{"version":"1.0","provider_name":"Malaysian Tribune","provider_url":"https:\/\/malaysiantribune.com","author_name":"admin","author_url":"https:\/\/malaysiantribune.com\/author\/admin\/","title":"Helsinn Group and BridgeBio Pharma\u2019s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ\u2122 (infigratinib) for Patients with Cholangiocarcinoma - Malaysian Tribune","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"j9PaXyAKbl\"><a href=\"https:\/\/malaysiantribune.com\/helsinn-group-and-bridgebio-pharmas-affiliate-qed-therapeutics-announce-health-canada-conditional-approval-of-truseltiq-infigratinib-for-patients-with-cholangiocarcinoma\/\">Helsinn Group and BridgeBio Pharma\u2019s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ\u2122 (infigratinib) for Patients with Cholangiocarcinoma<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/malaysiantribune.com\/helsinn-group-and-bridgebio-pharmas-affiliate-qed-therapeutics-announce-health-canada-conditional-approval-of-truseltiq-infigratinib-for-patients-with-cholangiocarcinoma\/embed\/#?secret=j9PaXyAKbl\" width=\"600\" height=\"338\" title=\"&#8220;Helsinn Group and BridgeBio Pharma\u2019s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ\u2122 (infigratinib) for Patients with Cholangiocarcinoma&#8221; &#8212; Malaysian Tribune\" data-secret=\"j9PaXyAKbl\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","description":"Helsinn Group and BridgeBio Pharma\u2019s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ\u2122 (infigratinib) for Patients with Cholangiocarcinoma \u2013 Health Canada Issues Conditional Approval of TRUSELTIQ under Project Orbis (September 27th, 2021) LUGANO, Switzerland, and PALO ALTO, CA, September 29, 2021 \u2013 Helsinn Group and BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate [\u2026]"}